Randomized Trialhigh evidence
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
Nature medicine·March 1, 2026·PMID 41514038
Why it mattersThis is the first randomized evidence that a BCMA-directed CAR T cell therapy can produce sustained, clinically meaningful improvements in generalized myasthenia gravis, including in biologic-naive patients, offering a potential new treatment paradigm targeting pathogenic plasma cells.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled